نتائج البحث - "Barry R, Davies"

1

AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors

المساهمون: Institut Català de la Salut, [Dunn S] Wellcome Sanger Institute, Cambridge, UK. Bioscience, Early Oncology, AstraZeneca, Cambridge, UK. [Eberlein C, Yelland U] Bioscience, Early Oncology, AstraZeneca, Alderley Park, UK. [Yu J] Wellcome Sanger Institute, Cambridge, UK. Molecular Biology of Metabolism Lab, The Francis Crick Institute, London, UK. [Gris-Oliver A, Serra V] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Ong SH] Wellcome Sanger Institute, Cambridge, UK, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Cancer Research, Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm [PHENOMENA AND PROCESSES], Class I Phosphatidylinositol 3-Kinases, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Medicaments antineoplàstics - Ús terapèutic, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Breast Neoplasms, Antineoplastic Agents, Mechanistic Target of Rapamycin Complex 1, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Phosphatidylinositol 3-Kinases, Cell Line, Tumor, Genetics, Humans, Guanine Nucleotide Exchange Factors, Other subheadings::/therapeutic use [Other subheadings], Protein Kinase Inhibitors, Molecular Biology, Phosphoinositide-3 Kinase Inhibitors, Resistència als medicaments, fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicos [FENÓMENOS Y PROCESOS], neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], Otros calificadores::/uso terapéutico [Otros calificadores], TOR Serine-Threonine Kinases, PTEN Phosphohydrolase, acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS], Mama - Càncer - Tractament, Female, Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS], Proto-Oncogene Proteins c-akt

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a9e136f779ccbe55fa005a37d201d30Test
https://hdl.handle.net/11351/8698Test

2

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

المصدر: Clin Cancer Res

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, Paclitaxel, Class I Phosphatidylinositol 3-Kinases, DNA Mutational Analysis, AKT1, P70-S6 Kinase 1, Breast Neoplasms, Tuberous Sclerosis Complex 1 Protein, Article, 03 medical and health sciences, Mice, 0302 clinical medicine, Breast cancer, Antineoplastic Combined Chemotherapy Protocols, medicine, Biomarkers, Tumor, PTEN, Animals, Humans, Pyrroles, Breast, Protein kinase B, Protein Kinase Inhibitors, PI3K/AKT/mTOR pathway, Mastectomy, biology, Fulvestrant, business.industry, TOR Serine-Threonine Kinases, Ribosomal Protein S6 Kinases, 70-kDa, medicine.disease, Prognosis, Metastatic breast cancer, Xenograft Model Antitumor Assays, 030104 developmental biology, Pyrimidines, Oncology, Chemotherapy, Adjuvant, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Mutation, biology.protein, Cancer research, Female, business, Proto-Oncogene Proteins c-akt, medicine.drug, Signal Transduction

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef93ddf12491d1bbf7d5667c25fa96d7Test
https://pubmed.ncbi.nlm.nih.gov/32220884Test

3

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

المساهمون: Institut Català de la Salut, [Turner NC] Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK. Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK. [Alarcón E] Clinical Oncology Department, British American Hospital, Lima, Peru. [Armstrong AC] Department of Medical Oncology, Christie Hospital NHS Foundation Trust and Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. [Philco M] Peruvian Institute of Oncology Radiotherapy, Lima, Peru. [López Chuken YA] University Hospital, Monterrey, Mexico. [Sablin MP] Department of Drug Development and Innovation (D3i), Curie Institute, Paris, France. [Oliveira, M] Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Hospital Universitari Vall d'Hebron

المصدر: Scientia
Recercat. Dipósit de la Recerca de Catalunya
instname
Annals of oncology : official journal of the European Society for Medical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Annals of Oncology
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)

مصطلحات موضوعية: 0301 basic medicine, Oncology, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Estrogen receptor, aminoácidos, péptidos y proteínas::proteínas::receptores citoplásmicos y nucleares::receptores de esteroides::receptores de estrógenos [COMPUESTOS QUÍMICOS Y DROGAS], Other subheadings::Other subheadings::/drug therapy [Other subheadings], AKT inhibitor, ER+, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Breast Tumors, Neoplasm Metastasis, education.field_of_study, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], Neoplasms::Neoplastic Processes::Neoplasm Metastasis [DISEASES], Hematology, Metastatic breast cancer, Survival Rate, Receptors, Estrogen, Paclitaxel, Tolerability, 030220 oncology & carcinogenesis, Female, metastatic breast cancer, medicine.medical_specialty, Class I Phosphatidylinositol 3-Kinases, Population, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Breast Neoplasms, capivasertib, 03 medical and health sciences, Breast cancer, Double-Blind Method, Metàstasi, Internal medicine, Biomarkers, Tumor, medicine, Humans, Pyrroles, education, Survival rate, neoplasms, business.industry, Amino Acids, Peptides, and Proteins::Proteins::Receptors, Cytoplasmic and Nuclear::Receptors, Steroid::Receptors, Estrogen [CHEMICALS AND DRUGS], Cancer, HER2−, Original Articles, PIK3CA, medicine.disease, Pyrimidines, 030104 developmental biology, chemistry, Estrògens - Receptors, neoplasias::procesos neoplásicos::metástasis neoplásica [ENFERMEDADES], Mutation, Mama - Càncer - Tractament, Neoplasm Recurrence, Local, business, Proto-Oncogene Proteins c-akt

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e859acd761a1223f94f5a89e6ed174abTest
https://hdl.handle.net/11351/5759Test

4

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

المؤلفون: Stephen Green, Sylvie Guichard, Robert McEwen, Barry R. Davies, Urszula M. Polanska, Zoe Howard, Teresa Klinowska, Celina M. D'Cruz, Michael Grondine, Christine M. Chresta, Teeru Bihani, Graham Bigley, James W.T. Yates, Kurt Gordon Pike, Jon Curwen, Sabina Cosulich, Oona Delpuech, Martin Pass

المصدر: Molecular Cancer Therapeutics. 14:2508-2518

مصطلحات موضوعية: Cancer Research, Morpholines, Immunoblotting, Breast Neoplasms, Mechanistic Target of Rapamycin Complex 2, Mice, SCID, mTORC1, Mechanistic Target of Rapamycin Complex 1, Biology, Pharmacology, mTORC2, Drug Administration Schedule, Mice, Inbred NOD, Cell Line, Tumor, Antineoplastic Combined Chemotherapy Protocols, medicine, Animals, Humans, Fulvestrant, Protein Kinase Inhibitors, PI3K/AKT/mTOR pathway, Cell Proliferation, Mice, Knockout, Serine/threonine-specific protein kinase, Estradiol, Cell growth, TOR Serine-Threonine Kinases, Xenograft Model Antitumor Assays, Tumor Burden, HEK293 Cells, Pyrimidines, Receptors, Estrogen, Oncology, Multiprotein Complexes, Benzamides, MCF-7 Cells, Hormonal therapy, Female, Signal Transduction, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::689b8ba235f8b435652d9591e5d9196fTest
https://doi.org/10.1158/1535-7163.mct-15-0365Test

5

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research. 24(9)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::f9acd74e189fd6e03233b7508787b5c1Test
https://pubmed.ncbi.nlm.nih.gov/29374052Test

6

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models

المؤلفون: Phillippa Dudley, Neil H. James, Claire Crafter, John Vincent, Barry R. Davies, Teresa Klinowska, Eric Tang

المصدر: International Journal of Oncology

مصطلحات موضوعية: MAPK/ERK pathway, Cancer Research, Receptor, ErbB-2, feedback, Breast Neoplasms, Pharmacology, Biology, Receptor tyrosine kinase, combination therapy, Mice, Trastuzumab, Cell Line, Tumor, Antineoplastic Combined Chemotherapy Protocols, medicine, PI3K/AKT/mTOR, Animals, Humans, Pyrroles, HER2-amplified breast cancer, skin and connective tissue diseases, Protein kinase B, PI3K/AKT/mTOR pathway, Cell Proliferation, Cell growth, Gene Amplification, Cancer, Drug Synergism, Articles, medicine.disease, Xenograft Model Antitumor Assays, AZD5363, Pyrimidines, Oncology, Drug Resistance, Neoplasm, MCF-7 Cells, Quinazolines, biology.protein, Phosphorylation, Female, Proto-Oncogene Proteins c-akt, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e16a0e9136df3078b9af2fd2524426a6Test
https://doi.org/10.3892/ijo.2015.3062Test

7

Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors

المؤلفون: Eeva Sommer, Dario R. Alessi, Barry R. Davies, Darren Cross, Sylvie Guichard, Hannah Dry

المصدر: Biochemical Journal. 452:499-508

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac6f9cdd02b445a137e64a9f423bfc8aTest
https://doi.org/10.1042/bj20130342Test

8

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

المصدر: Molecular Cancer Therapeutics. 11:873-887

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e98875526525d3b19c1c9f1c3c90aab9Test
https://doi.org/10.1158/1535-7163.mct-11-0824-tTest

9

AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo

المؤلفون: Elisabetta Marangoni, Barry R. Davies, Sunil Pancholi, Urszula M. Polanska, Gianmaria Liccardi, Mitch Dowsett, Aurélie Thuleau, Stephanie K. Guest, Qiong Gao, Lesley-Ann Martin, Nikiana Simigdala, Ricardo Ribas, Stephen R. D. Johnston, Aradhana Rani, Hayley Campbell

المصدر: Molecular cancer therapeutics. 14(9)

مصطلحات موضوعية: Transcriptional Activation, Cancer Research, medicine.medical_specialty, Antineoplastic Agents, Hormonal, medicine.drug_class, Estrogen receptor, Breast Neoplasms, Proto-Oncogene Proteins c-myc, Mice, Phosphatidylinositol 3-Kinases, Breast cancer, Internal medicine, Cell Line, Tumor, medicine, Animals, Cluster Analysis, Humans, Pyrroles, skin and connective tissue diseases, Protein kinase B, Fulvestrant, Protein Kinase Inhibitors, PI3K/AKT/mTOR pathway, Cell Proliferation, Estradiol, business.industry, Gene Expression Profiling, TOR Serine-Threonine Kinases, Drug Synergism, Cell Cycle Checkpoints, medicine.disease, Xenograft Model Antitumor Assays, GREB1, Disease Models, Animal, Endocrinology, Pyrimidines, Oncology, Receptors, Estrogen, Estrogen, Drug Resistance, Neoplasm, Cancer research, Female, business, Proto-Oncogene Proteins c-akt, Tamoxifen, medicine.drug, Signal Transduction

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69a838f029c2c37adf844f5868e07943Test
https://pubmed.ncbi.nlm.nih.gov/26116361Test

10

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase

المساهمون: Fu, Xiaoyong, Creighton, Chad J., Biswal, Nrusingh C., Kumar, Vijetha, Shea, Martin, Herrera, Sabrina, Contreras, Alejandro, Gutierrez, Carolina, Wang, Tao, Nanda, Sarmistha, Giuliano, Mario, Morrison, Glady, Nardone, Agostina, Karlin, Kristen L., Westbrook, Thomas F., Heiser, Laura M., Anur, Pavana, Spellman, Paul, Guichard, Sylvie M., Smith, Paul D., Davies, Barry R., Klinowska, Teresa, Lee, Adrian V., Mills, Gordon B., Rimawi, Mothaffar F., Hilsenbeck, Susan G., Gray, Joe W., Joshi, Amit, Osborne, C. K., Schiff, Rachel

المصدر: Breast Cancer Research : BCR

مصطلحات موضوعية: Cancer Research, Gene Expression, Mitogen-activated protein kinase kinase, Mitogen-Activated Protein Kinase, Phosphatidylinositol 3-Kinases, MCF-7 Cell, Sirolimu, ASK1, Molecular Targeted Therapy, Fulvestrant, Medicine(all), TOR Serine-Threonine Kinase, biology, Estradiol, TOR Serine-Threonine Kinases, 3. Good health, Editorial, Oncology, Receptors, Estrogen, Doxycycline, Gene Knockdown Techniques, MCF-7 Cells, Female, Mitogen-Activated Protein Kinases, Breast Neoplasm, Research Article, Human, Signal Transduction, Xenograft Model Antitumor Assay, Neoplasms, Hormone-Dependent, Antineoplastic Agents, Hormonal, Protein Kinase Inhibitor, Mice, Nude, Breast Neoplasms, PTEN, Animals, Humans, c-Raf, Protein kinase B, Protein Kinase Inhibitors, PI3K/AKT/mTOR pathway, Sirolimus, Animal, Cyclin-dependent kinase 4, Akt/PKB signaling pathway, PTEN Phosphohydrolase, Xenograft Model Antitumor Assays, Tamoxifen, Drug Resistance, Neoplasm, Gene Knockdown Technique, biology.protein, Cancer research, Phosphatidylinositol 3-Kinase, Proto-Oncogene Proteins c-akt

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49b8e05d376b25b5859d608cc00f5d0fTest
https://pubmed.ncbi.nlm.nih.gov/25888162Test

تنقيح النتائج